Effect of a Vegan Mediterranean Diet on Cardiometabolic Biomarkers, Functional Capacity, and Quality of Life in Patients with Fibromyalgia
FIBROVEG
1 other identifier
interventional
28
0 countries
N/A
Brief Summary
This study aims to evaluate the effect of a vegan Mediterranean diet compared to a traditional Mediterranean diet on inflammatory biomarkers, functional capacity, and quality of life in patients with fibromyalgia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started Mar 2025
Shorter than P25 for phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 27, 2025
CompletedFirst Posted
Study publicly available on registry
February 3, 2025
CompletedStudy Start
First participant enrolled
March 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 14, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 21, 2025
CompletedFebruary 3, 2025
January 1, 2025
1 month
January 27, 2025
January 31, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Neutrophil to lymphocyte ratio
Lymphocyte and neutrophil concentrations will be measured with the HemoCue® WBC DIFF system (HemoCue AB, Ängelholm, Sweden).The Neutrophil-to-Lymphocyte Ratio (NLR) is a simple inflammatory biomarker calculated by dividing neutrophil count by lymphocyte count. It reflects the balance between inflammation (neutrophils) and immune regulation (lymphocytes). An elevated NLR is associated with chronic inflammation, physiological stress, or immune dysfunction, while lower levels indicate a more balanced immune state. Its ease of measurement and broad applicability make it valuable for monitoring inflammatory, cardiovascular, and oncological conditions.
From enrollment to the end of treatment at 6 weeks
Lipid profile
The concentrations of total cholesterol and cholesterol-LDL will be measured with a POC multi-parameter lux meter (Biochemical Systems International, Italy).
From enrollment to the end of treatment at 6 weeks
Cardiorespiratory fitness
The 30s Chair-to-Stand (CS) test assesses lower trunk strength by counting how many times a person can stand up and sit down within 30 seconds. It is commonly used to evaluate functional mobility and endurance in older adults or individuals with certain health conditions.
From enrollment to the end of treatment at 6 weeks
Quality life
The Fibromyalgia Impact Questionnaire (FIQ) examines the impact of fibromyalgia on daily life, covering areas such as functional capacity, pain, fatigue, sleep, and psychological well-being. Its revised version (FIQ-revised) focuses more on functional capacity, symptoms, and the overall impact of fibromyalgia on the individual's daily life.
From enrollment to the end of treatment at 6 weeks
Metabolic health
Visceral fat is the fat stored within the abdominal cavity around internal organs. It is commonly measured to assess the risk of metabolic diseases, such as type 2 diabetes and cardiovascular conditions.
From enrollment to the end of treatment at 6 weeks
Secondary Outcomes (5)
Metabolic health
From enrollment to the end of treatment at 6 weeks
Metabolic health
From enrollment to the end of treatment at 6 weeks
Strength performance
From enrollment to the end of treatment at 6 weeks
Quality Life
From enrollment to the end of treatment at 6 weeks
Quality life
From enrollment to the end of treatment at 6 weeks
Study Arms (2)
Vegan Mediterranean diet
EXPERIMENTALThe vegan mediterranean diet is mainly composed of whole plant-based foods, similar to a Mediterranean diet, but the animal sources of protein and fat are substituted with plant foods rich in protein and fat. During the vegan diet, participants are supplemented with 1000 µg of cyanocobalamin (vitamin B12) twice a week (Harrison Sports Nutrition, Granada, Spain) to compensate for the deficiency in vitamin B12 intake induced by the vegan diet.
Mediterranean diet
ACTIVE COMPARATORThe traditional Mediterranean diet contains an abundant intake of whole plant-based foods, with moderate to low consumption of fish, poultry, low-fat dairy products, and eggs, very low consumption of red and processed meats, and no sweets. Olive oil is the main added fat, and animal protein accounts for 60% of total protein intake.
Interventions
The vegan mediterranean diet is mainly composed of whole plant-based foods, similar a una dieta mediterránea, but the animal sources of protein and fat are substituted with plant foods rich in protein and fat. During the vegan diet, participants are supplemented with 1000 µg of cyanocobalamin (vitamin B12) twice a week (Harrison Sports Nutrition, Granada, Spain) to compensate for the deficiency in vitamin B12 intake induced by the vegan diet.
Eligibility Criteria
You may qualify if:
- Adults aged between 18 and 50 years.
- Participants with a Fibromyalgia diagnosis according to the American College of Rheumatology (ACR) criteria.
- Functional independence.
- Non-smokers.
- Low alcohol consumption (\<1 serving/day).
- Pharmacological treatment stabilized for at least 4 weeks prior to the start of the study.
You may not qualify if:
- Pregnant, lactating, or menopausal women.
- Physical condition that prevents the performance of functional capacity tests.
- Change in pharmacological therapy during the intervention period.
- Concomitant inflammatory conditions.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 27, 2025
First Posted
February 3, 2025
Study Start
March 1, 2025
Primary Completion
April 14, 2025
Study Completion
April 21, 2025
Last Updated
February 3, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share
In our study, the sharing of individual participant data (IPD) is not required as part of the trial registration process on ClinicalTrials.gov. The study does not involve sharing identifiable participant information or IPD for secondary analyses or public access